Table 1.
Women | Men | |||||
---|---|---|---|---|---|---|
Without MI | With MI | Without MI | With MI | |||
n=4,926 | n=472 | p-value | n=5,773 | n=528 | p-value | |
Age (years), mean (SD) | 76.8 (9.4) | 79.8 (8.0) | <0.001 | 71.7 (10.3) | 75.6 (8.8) | <0.001 |
Age group (years) | <0.001 | <0.001 | ||||
45–54 | 101 (2.1) | 1 (0.2) | 352 (6.1) | 14 (2.7) | ||
55–64 | 484 (9.8) | 23 (4.9) | 1,119 (19.4) | 55 (10.4) | ||
65–74 | 1,144 (23.2) | 75 (15.9) | 1,795 (31.1) | 132 (25.0) | ||
75–84 | 2,176 (44.2) | 246 (52.2) | 1,943 (33.7) | 261 (49.4) | ||
85+ | 1,021 (20.7) | 127 (26.9) | 564 (9.8) | 66 (12.5) | ||
Neighborhood SES | 0.043 | 0.016 | ||||
High | 1,729 (35.1) | 146 (30.9) | 2,330 (40.4) | 200 (37.9) | ||
Middle | 2,420 (49.1) | 233 (49.4) | 2,646 (45.8) | 231 (43.8) | ||
Low | 777 (15.8) | 93 (19.7) | 797 (13.8) | 97 (18.4) | ||
Marital status | 0.002 | <0.001 | ||||
Married | 1,485 (30.3) | 115 (24.5) | 3,443 (59.9) | 298 (56.7) | ||
Unmarried | 361 (7.4) | 26 (5.5) | 561 (9.8) | 40 (7.6) | ||
Divorced | 695 (14.2) | 60 (12.8) | 903 (15.7) | 74 (14.1) | ||
Widowed | 2,362 (48.2) | 268 (57.1) | 844 (14.7) | 114 (21.7) | ||
Educational level | <0.001 | <0.001 | ||||
Compulsory school | 2,240 (51.5) | 236 (59.8) | 2,114 (38.6) | 238 (48.2) | ||
Secondary school | 1,442 (33.2) | 126 (31.9) | 2,068 (37.8) | 173 (35.0) | ||
College/university | 665 (15.3) | 33 (8.3) | 1,292 (23.6) | 83 (16.8) | ||
AF-related disease | ||||||
Hypertension | 2,394 (48.6) | 239 (50.6) | 0.40 | 2,377 (41.2) | 236 (44.7) | 0.12 |
CHD | 801 (16.3) | 210 (44.5) | <0.001 | 849 (14.7) | 255 (48.3) | <0.001 |
Heart failure | 974 (19.8) | 116 (24.6) | 0.013 | 933 (16.2) | 133 (25.2) | <0.001 |
Valvular disease | 232 (4.7) | 33 (7.0) | 0.028 | 254 (4.4) | 25 (4.7) | 0.72 |
Cardiomyopathy | 27 (0.6) | 1 (0.2) | 0.51 | 53 (0.9) | 5 (1.0) | 0.95 |
CVS | 582 (11.8) | 48 (10.2) | 0.29 | 638 (111) | 49 (9.3) | 0.22 |
Diabetes mellitus | 914 (18.6) | 120 (25.4) | 0.001 | 1,072 (18.6) | 134 (25.4) | 0.001 |
Drugs | ||||||
Ever warfarin | 2,381 (48.3) | 187 (39.6) | <0.001 | 3,227 (55.9) | 272 (51.5) | 0.052 |
Warfarin ITT | 2,296 (46.6) | 158 (33.5) | <0.001 | 3,118 (54.0) | 241 (45.6) | <0.001 |
Warfarin PP | 1,679 (34.1) | 67 (14.2) | <0.001 | 2,229 (38.6) | 97 (18.4) | <0.001 |
Ever ASA | 2,786 (56.6) | 330 (69.9) | <0.001 | 2,910 (50.4) | 352 (66.7) | <0.001 |
ASA ITT | 2,461 (50.0) | 296 (62.7) | <0.001 | 2,584 (44.8) | 299 (56.6) | <0.001 |
ASA PP | 1,479 (30.0) | 125 (26.5) | 0.11 | 1,614 (28.0) | 124 (23.5) | 0.028 |
Ever clopidogrel | 122 (2.5) | 40 (8.5) | <0.001 | 111 (1.9) | 59 (11.2) | <0.001 |
Clopidogrel ITT | 89 (1.8) | 8 (1.7) | 0.58 | 91 (1.6) | 10 (1.9) | 0.86 |
Clopidogrel PP | 38 (0.8) | 4 (0.9) | 0.78 | 34 (0.6) | 6 (1.1) | 0.13 |
Prescription of warfarin was classified as “intention-to-treat” (“ITT”) if ever present before the years of MI, or present among subjects without MI. Prescription of warfarin was classified as “per-protocol” (“PP”) if present the year before and the year of first MI, or present among subjects without MI if present during at least three years, at least 50% of actual years after first recorded year of AF, or during both 2006 and 2007.